Why Should Pfizer Stock Holders Watch This One Number?
For questions about this article or underlying research, email help@trefis.com.
Pfizer (PFE) earned $4.33 billion in net income from July 2025 to June 2026, down from $10.8 billion a year earlier. This matters to anyone holding the stock for income, because Pfizer paid out $9.79 billion in dividends over the same twelve months, exceeding what it earned. Sales barely moved, coming in at $63.7 billion against $63.8 billion. So where did the rest of Pfizer’s profit go? Part of the answer is $4.3 billion in non-cash write-downs recorded in fiscal Q2 2026.
Pfizer Posted Losses In Two Of Four Recent Quarters
Two of the last four quarters ended in losses, while the other two were profitable. In fiscal Q4 2025, Pfizer lost $1.65 billion on sales of $17.6 billion. In fiscal Q2 2026, it recorded a $248 million loss, compared with net income of $2.91 billion a year earlier.
Management tied the fiscal Q2 2026 result to $4.3 billion in non-cash write-downs on intangible assets, recorded during that quarter. The company said these charges followed the results of a late-stage lung cancer trial and, to a lesser extent, the removal of its revenue forecast for Oxbryta after discussions with the FDA.
Pfizer kept 6.8% of its sales as net income over the twelve months to June 2026, down from 16.8% a year earlier. Its twelve-month net margin has been lower at only three of the 40 quarter-ends since fiscal Q3 2016.
How Is Pfizer Stock Priced Against Its Lower Profit?
Based on reported profit, Pfizer stock costs more than the market. At the October 27, 2026 close, it traded at 39.2 times its twelve-month earnings, against 22.6 for the S&P 500. Priced on sales, the stock costs less, trading at 2.7 times against 3.2 for the index.
Management measures profit its own way, and the latest quarter looks very different by that standard. Pfizer reported a loss of $0.04 per share in fiscal Q2 2026, while management’s adjusted figure was a profit of $0.77 per share.
Buyers have not stayed away. The stock returned 28.8% over the year to October 27, 2026, compared with 15.0% for the S&P 500.
Is Pfizer Still Generating Enough Cash For Dividends?
Over twelve months, yes. Pfizer’s free cash flow was $11.0 billion from July 2025 to June 2026, which was more than it paid in dividends, though down from $12.4 billion a year earlier. Operating income, the profit from running the business, held steady at $17.0 billion against $16.7 billion a year earlier. Even in fiscal Q2 2026, when Pfizer posted a net loss, its operating income reached $3.54 billion.
The first half of 2026 was weaker. Pfizer generated $2.48 billion of free cash flow in those six months, about half of the $4.9 billion management said it returned through its quarterly dividend. Management also said Pfizer made its final repatriation tax payment, about $2.6 billion, in the second quarter. On the August 4, 2026 call, management said it was extremely confident the dividend will be maintained even in its most stretched scenarios, and that dividend growth will resume after the loss-of-exclusivity period.
Pfizer’s net income deserves close attention from holders. Still, since sales and operating income held steady, it is a risk to weigh rather than an alarm. Further write-downs would add to the worry, and management expects leverage to stay around its current level or rise modestly as it absorbs the loss of exclusivity on some drugs over the next few years. Management also said the third quarter will include a $650 million expense for an upfront payment in its Innovent Biologics deal. Pfizer is expected to report its fiscal Q3 2026 results in November 2026, and net income for that quarter is the figure to watch.
Who Is Watching Your Portfolio’s Risk When You’re Not?
Pfizer is one risk to keep an eye on, and most portfolios hold many. Watching all of them, day after day, is hard to do alone. Our partner advisory firm builds portfolios on Trefis research, starting with the HQ Portfolio, whose edge has been limiting losses when markets fall. Talk it through on a free 30-minute call, and bring your hardest questions.
Spot an error or want more like this? Tell us in 10 seconds.